Format

Send to

Choose Destination
Am J Med. 2016 Nov;129(11S):S54-S63. doi: 10.1016/j.amjmed.2016.06.006. Epub 2016 Aug 26.

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.

Author information

1
Departments of Neurology and Surgery and Perioperative Care, Seton Dell Medical School Stroke Institute, Austin, TX. Electronic address: TMilling@seton.org.
2
Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Hofstra North Shore-LIJ School of Medicine, North Shore-LIJ Health System, Manhasset, NY.

Abstract

Direct oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant armamentarium, and provide an alternative to the use of vitamin K antagonists such as warfarin. Regardless of the type of agent used, bleeding is the major complication of anticoagulant therapy. The decision to restart oral anticoagulation following a major hemorrhage in a previously anticoagulated patient is supported largely by retrospective studies rather than randomized clinical trials (mostly with vitamin K antagonists), and remains an issue of individualized clinical assessment: the patient's risk of thromboembolism must be balanced with the risk of recurrent major bleeding. This review provides guidance for clinicians regarding if and when a patient should be re-initiated on DOAC therapy following a major hemorrhage, based on the existing evidence.

KEYWORDS:

Direct-acting oral anticoagulants; Gastrointestinal bleeding; Intracranial hemorrhage; Major hemorrhage; Restart oral anticoagulants; Warfarin

PMID:
27569671
PMCID:
PMC5568864
DOI:
10.1016/j.amjmed.2016.06.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center